Nanovesicles engineered from ES cells for enhanced cell proliferation

Area of Science:

• Biotechnology
• Regenerative Medicine
• Cell Biology

Background:

• Extracellular vesicles (EVs), including exosomes and microvesicles, are crucial for intercellular communication but face limitations in isolation and quantity for therapeutic use.
• Rarity and heterogeneity of exosomes hinder their diagnostic and therapeutic potential, especially in regenerative medicine.
• Existing isolation methods for exosomes are often lengthy and inefficient, posing challenges for large-scale applications.

Purpose of the Study:

• To develop and evaluate novel cell-derived nanovesicles as an alternative to exosomes for therapeutic applications.
• To investigate the potential of these nanovesicles to enhance cell proliferation and tissue repair.
• To assess the molecular mechanisms underlying the effects of nanovesicles on fibroblasts.

Main Methods:

• Generation of cell-derived nanovesicles by extruding living embryonic stem cells through micro-filters.
• Treatment of primary murine skin fibroblasts with the generated nanovesicles.
• Analysis of gene and protein expression levels (mRNA, VEGF-α, TGF-β, collagen I, PCNA, Ki-67) and cell proliferation rates.

Main Results:

• Nanovesicle treatment led to increased expression of proliferation markers (PCNA, Ki-67) and key proteins (VEGF-α, TGF-β, collagen I) in fibroblasts.
• Enhanced cell proliferation rate and cell number were observed in nanovesicle-treated fibroblasts compared to controls.
• The nanovesicles, possessing a lipid bilayer and cellular contents, demonstrated efficacy in stimulating fibroblast activity.

Conclusions:

• Cell-derived nanovesicles show promise as a therapeutic agent for promoting tissue recovery and wound healing.
• These nanovesicles offer a viable alternative to exosomes, overcoming limitations of rarity and complex isolation.
• Further research into nanovesicle applications could advance regenerative medicine and therapeutic strategies for tissue repair.